Company Description
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers.
It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
The company’s lead product candidate are UGN-102, UGN-103 which is in phase 3 of clinical trial for intravesical solution, and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC.
The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H.
to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 2004 |
| IPO Date | May 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 235 |
| CEO | Elizabeth Barrett |
Contact Details
Address: 400 Alexander Park Drive, 4th Floor Princeton, New Jersey 08540 United States | |
| Phone | 646 768 9780 |
| Website | urogen.com |
Stock Details
| Ticker Symbol | URGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001668243 |
| CUSIP Number | M96088105 |
| ISIN Number | IL0011407140 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Elizabeth A. Barrett | President, Chief Executive Officer and Director |
| Jason Drew Smith J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer |
| Christopher Degnan CPA | Chief Financial Officer |
| Vincent I. Perrone | Senior Director of Investor Relations |
| Bryon Wornson | Executive Vice President of Talent, Advocacy and Communications |
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research and Development and Technical Operations |
| James Ottinger R.ph. | Executive Vice President of Regulatory Affairs and Quality |
| Michael J. Louie M.D., M.P.H., M.Sc. | Executive Vice President of Medical Affairs and Clinical Development |
| David Lin | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 10, 2025 | 10-K | Annual Report |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Jan 14, 2025 | 8-K | Current Report |
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |